Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 2008 Aug;9(8):777-85
Date
08/02/2008Pubmed ID
18672213Pubmed Central ID
PMC3390774DOI
10.1016/S1470-2045(08)70197-9Scopus ID
2-s2.0-47849090505 (requires institutional sign-in at Scopus site) 89 CitationsAbstract
The Human Genome Project and HapMap have led to a better appreciation of the importance of common genetic variation in determining cancer risk, created potential for predicting response to therapy, and made possible the development of targeted prevention and therapeutic interventions. Advances in molecular epidemiology can be used to explore the role of genetic variation in modulating the risk for severe and persistent symptoms, such as pain, depression, and fatigue, in patients with cancer. The same genes that are implicated in cancer risk might also be involved in the modulation of therapeutic outcomes. For example, polymorphisms in several cytokine genes are potential markers for genetic susceptibility both for cancer risk and for cancer-related symptoms. These genetic polymorphisms are stable markers and easily and reliably assayed to explore the extent to which genetic variation might prove useful in identifying patients with cancer at high-risk of symptom development. Likewise, they could identify subgroups who might benefit most from symptom intervention, and contribute to developing personalized and more effective therapies for persistent symptoms.
Author List
Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, Bruera E, Shete SAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
CausalityComorbidity
Cytokines
Depressive Disorder
Fatigue
Female
Genetic Markers
Genetic Predisposition to Disease
Humans
Male
Molecular Epidemiology
Neoplasms
Pain, Intractable
Sensitivity and Specificity
Severity of Illness Index